| Literature DB >> 36034710 |
Li Xiong1, Junfeng Cao1, Xingyu Yang1, Shengyan Chen1, Mei Wu1, Chaochao Wang1, Hengxiang Xu1, Yijun Chen1, Ruijiao Zhang2, Xiaosong Hu2, Tian Chen2, Jing Tang3, Qin Deng3, Dong Li1, Zheng Yang2, Guibao Xiao3, Xiao Zhang2.
Abstract
Purpose: The Corona Virus Disease 2019 (COVID-19) pandemic has become a challenge of world. The latest research has proved that Xuanfei Baidu granule (XFBD) significantly improved patient's clinical symptoms, the compound drug improves immunity by increasing the number of white blood cells and lymphocytes, and exerts anti-inflammatory effects. However, the analysis of the effective monomer components of XFBD and its mechanism of action in the treatment of COVID-19 is currently lacking. Therefore, this study used computer simulation to study the effective monomer components of XFBD and its therapeutic mechanism.Entities:
Keywords: COVID-19; Xuanfei Baidu granule; bioinformatics analysis; molecular docking; molecular dynamics
Mesh:
Substances:
Year: 2022 PMID: 36034710 PMCID: PMC9399524 DOI: 10.3389/fcimb.2022.965273
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
The core active compounds in Xuanfei Baidu Granules (XFBD) Binding free energies and energy components.
| MOL_ID | Molecule Name | OB | MW | Alogp | Caco2 | BBB | DL |
|---|---|---|---|---|---|---|---|
| MOL013287 | Physovenine | 106.219 | 262.34 | 2.08 | 0.50 | 0.20 | 0.18 |
| MOL012922 | I-SPD | 87.34 | 327.41 | 3.09 | 0.75 | 0.20 | 0.54 |
| MOL007207 | Machiline | 79.64 | 285.37 | 2.82 | 0.78 | 0.08 | 0.23 |
| MOL005890 | pachypodol | 75.06 | 356.40 | 2.99 | 0.83 | 0.11 | 0.39 |
| MOL000500 | Vestitol | 74.65 | 272.32 | 3.14 | 0.85 | 0.29 | 0.20 |
OB, oral bioavailability.
MW, molecular weight.
BBB, blood brain barrier.
DL, drug similarity.
Figure 1Intersection targets-active ingredient networks. Targets of the intersection of Xuanfei Baidu granule (XFBD) and COVID-19.
Figure 2Protein-protein interaction (PPI) network. (A) PPI network of protein target, (B) PPI network of core protein target (confidence>0.95).
Figure 3Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of related genes. (A) The top 10 terms in biological processes (BP) were greatly enriched. (B) The subnetwork displayed the first 10 BP terms and related genes. (C) The top 10 terms in cellular components (CC) were greatly enriched. (D) The subnetwork displayed the first 10 CC terms and related genes. (E) The top 10 terms in molecular function (MF) were greatly enriched. (F) The subnetwork displayed the first 10 MF terms and related genes. (G) The first 15 KEGG pathways were showed. (H) the subnetworks displayed the first 15 KEGG pathways and related.
Figure 4Disease-core gene target-drug network. Square nodes represent gene targets, triangular nodes represent signaling pathways (KEGG), and octagonal nodes represent gene ontology (GO) of related genes.
Figure 5Molecular docking of active ingredients and core targets. (A) CSF2/I-SPD, (B) CSF2/Vestitol, (C) NLRP3/I-SPD, (D) NLRP3/Pachypodol.
Figure 6Screening docking results between ligands and receptors.
Figure 7Complex root mean square deviation (RMSD) difference over time. ns, nanosecond.
Binding free energies and energy components predicted by MM/GBSA (kcal/mol).
| System name | CSF2/I-SPD | CSF2/Vestitol | NLRP3/I-SPD | NLRP3/Pachypodol |
|---|---|---|---|---|
|
| -31.85 ± 0.83 | -35.21 ± 1.70 | -39.13 ± 4.72 | -26.90 ± 1.87 |
|
| -74.07 ± 6.98 | 1.43 ± 2.49 | -77.18 ± 10.66 | -15.70 ± 5.59 |
|
| 88.70 ± 7.47 | 10.83 ± 2.40 | 90.77 ± 6.69 | 24.61 ± 4.35 |
|
| -3.67 ± 0.11 | -4.63 ± 0.15 | -4.97 ± 0.18 | -3.65 ± 0.23 |
|
| -20.89 ± 1.32 | 27.57 ± 2.78 | -30.52 ± 1.17 | -21.65 ± 3.36 |
ΔEvdW: van der Waals energy.
ΔEelec: electrostatic energy.
ΔGGB: electrostatic contribution to solvation.
ΔGSA: non-polar contribution to solvation.
ΔGbind: binding free energy.
Figure 8Changes in the number of hydrogen bonds between small molecule ligands and protein receptors in complex system simulations (A) CSF2/I-SPD, (B) CSF2/Vestitol, (C) NLRP3/I-SPD, (D) NLRP3/Pachypodol.
Figure 9Changes in the stability of protein targets at the residue level (A) CSF2/I-SPD and CSF2/Vestitol. (B) NLRP3/I-SPD and NLRP3/Pachypodol.
Figure 10Analysis of protein folding state and overall conformation (A) CSF2/I-SPD and CSF2/Vestitol. (B) NLRP3/I-SPD and NLRP3/Pachypodol. ns, nanosecond.
Figure 11Analysis of Solvent Accessible Surface Area (SASA) (A) CSF2/I-SPD and CSF2/Vestitol. (B) NLRP3/I-SPD and NLRP3/Pachypodol. ns, nanosecond.